![Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis | Business Wire Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis | Business Wire](https://mms.businesswire.com/media/20210728005045/en/894218/5/Teva_2020_Economic_Impact_Report_Infographic_26_July_2021.jpg)
Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis | Business Wire
![New York Attorney General Letitia James secures $523 million from Teva Pharmaceuticals for role in opioid crisis - ABC17NEWS New York Attorney General Letitia James secures $523 million from Teva Pharmaceuticals for role in opioid crisis - ABC17NEWS](https://abc17news.b-cdn.net/abc17news.com/2022/11/hypatia-h_8f1f3ca0ec96e5b50d6e6bb7feaaac57-h_d987bb9adc3c469fbdc3d3f36d48ecd3-300.jpg)
New York Attorney General Letitia James secures $523 million from Teva Pharmaceuticals for role in opioid crisis - ABC17NEWS
![Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1601469710/Copaxone.jpg/Copaxone.jpg?VersionId=PhbA.kpjNFb3A_uch5krsTbbBmdM_mNL)
Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone | Fierce Pharma
![Teva Announces Availability of a Generic Equivalent of EpiPen Jr® Auto-Injector in the United States | SnackSafely.com Teva Announces Availability of a Generic Equivalent of EpiPen Jr® Auto-Injector in the United States | SnackSafely.com](https://media.snacksafely.com/wp-content/uploads/2019/01/Teva-Auto-Injectors.jpg)
Teva Announces Availability of a Generic Equivalent of EpiPen Jr® Auto-Injector in the United States | SnackSafely.com
![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg)